Genome-Wide Association Analysis Identifies a Mutation in the Thiamine Transporter 2 (SLC19A3) Gene Associated with Alaskan Husky Encephalopathy by Runstadler, Jonathan et al.
Genome-Wide Association Analysis Identifies a Mutation
in the Thiamine Transporter 2 (SLC19A3) Gene
Associated with Alaskan Husky Encephalopathy
Karen M. Vernau1*, Jonathan A. Runstadler2¤, Emily A. Brown1, Jessie M. Cameron3, Heather J. Huson2,
Robert J. Higgins2, Cameron Ackerley3, Beverly K. Sturges1, Peter J. Dickinson1, Birgit Puschner1,
Cecilia Giulivi1, G. Diane Shelton4, Brian H. Robinson3, Salvatore DiMauro5, Andrew W. Bollen6,
Danika L. Bannasch1
1University of California Davis, Davis, California, United States of America, 2University of Alaska Fairbanks, Fairbanks, Alaska, United States of America, 3 Research
Institute, The Hospital for Sick Children, Toronto, Ontario, Canada, 4Department of Pathology, University of California San Diego, La Jolla, California, United States of
America, 5Department of Neurology, Columbia University Medical Center, New York, New York, United States of America, 6Department of Pathology, School of Medicine,
University of California San Francisco, San Francisco, California, United States of America
Abstract
Alaskan Husky Encephalopathy (AHE) has been previously proposed as a mitochondrial encephalopathy based on
neuropathological similarities with human Leigh Syndrome (LS). We studied 11 Alaskan Husky dogs with AHE, but found no
abnormalities in respiratory chain enzyme activities in muscle and liver, or mutations in mitochondrial or nuclear genes that
cause LS in people. A genome wide association study was performed using eight of the affected dogs and 20 related but
unaffected control AHs using the Illumina canine HD array. SLC19A3 was identified as a positional candidate gene. This gene
controls the uptake of thiamine in the CNS via expression of the thiamine transporter protein THTR2. Dogs have two copies
of this gene located within the candidate interval (SLC19A3.2 – 43.36–43.38 Mb and SLC19A3.1 – 43.411–43.419 Mb) on
chromosome 25. Expression analysis in a normal dog revealed that one of the paralogs, SLC19A3.1, was expressed in the
brain and spinal cord while the other was not. Subsequent exon sequencing of SLC19A3.1 revealed a 4bp insertion and SNP
in the second exon that is predicted to result in a functional protein truncation of 279 amino acids (c.624 insTTGC, c.625
C.A). All dogs with AHE were homozygous for this mutation, 15/41 healthy AH control dogs were heterozygous carriers
while 26/41 normal healthy AH dogs were wild type. Furthermore, this mutation was not detected in another 187 dogs of
different breeds. These results suggest that this mutation in SLC19A3.1, encoding a thiamine transporter protein, plays a
critical role in the pathogenesis of AHE.
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Introduction
Alaskan Husky Encephalopathy (AHE) is a fatal brain disease in
young Alaskan Husky (AH) dogs, often affecting multiple dogs
from the same litter [1,2]. AHE was initially described in 13 dogs
from the northern United States, including Alaska, Massachusetts,
New York, Wyoming, Maine and Minnesota [1]. Based on the
clinical and neuropathological similarities to Leigh Syndrome (LS)
in people, AHE was proposed to be a mitochondrial encephalop-
athy. Human LS includes a group of diseases with heterogeneous
clinical symptoms, usually characterized by elevations in blood
lactate and respiratory chain enzyme dysfunction(s), and due to
various mutations in either nuclear or mitochondrial DNA. An
almost identical clinicopathological disease to AHE is described in
11 European Yorkshire terriers without a defined underlying cause
[3].
Dogs with AHE may have acute onset of clinical signs, or
chronic progressive waxing and waning clinical history. Typically,
they have multifocal central nervous system deficits including
seizures, altered mentation, dysphagia, absent menace response,
central blindness, hypermetria, proprioceptive positioning deficits,
facial hypoalgesia, ataxia and tetraparesis.
Diagnostic testing reported in dogs with AHE was limited to
normal serum and cerebrospinal fluid pyruvate and lactate
concentrations; evaluation of mitochondrial respiratory chain
enzymes was not done. Two dogs also had intracranial imaging.
Computed tomography images in one dog had bilateral
hypoattenuating lesions in the thalamus, and MR images of the
other dog had bilateral hyperintense lesions in the brainstem on
T2 weighted images. All dogs died or were euthanized, most
within 2–7 months, however one dog lived for 1 year after the
onset of clinical signs when it died of ‘‘natural causes’’ [1,2].
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In people and domestic animals, a multitude of uncommon
diseases are associated with bilateral and symmetrically distributed
brain lesions, apparent on magnetic resonance imaging and/or
neuropathology. Examples include toxicities (carbon monoxide
poisoning), metabolic (Leigh Syndrome [4], hypoxic-ischemic
encephalopathy, hypoglycemia, biotin responsive basal ganglia
disease [5], Wernicke’s-like encephalopathy [6]), inflammatory
(Neuro Behcet disease), nutritional (thiamine deficiency enceph-
alopathy [7]), vascular (deep cerebral vein thrombosis), infectious
(bovine spongiform encephalopathy, Creutzfeld-Jakob disease),
and inborn errors of metabolism (L-2 hydoxyglutamic aciduria [8],
citrullinemia). A systematic diagnostic approach to this group of
disorders is essential to ensure that a specific diagnosis can be
rendered in a timely manner.
In people, mutations in the SLC19A3 gene (encoding a thiamine
transporter protein) are associated with encephalopathies that
have some clinical and neuropathologic similarities to AHE [9]. In
this study, 11 dogs with neuropathologically and/or neuroradio-
logically confirmed AHE were evaluated for 1) mitochondrial
respiratory chain enzyme functions; 2) light and electron
microscopical pathological studies on skeletal muscle and liver,
and 3) a genome wide association study utilizing the Illumina
canine HD array. Together, our findings suggest that the
pathogenesis of AHE results from a genetic defect in a thiamine
transporter (SLC19A3), and is not a primary mitochondrial
encephalopathy.
Results
Clinical Findings and Outcome in dogs with AHE
All 11 dogs with AHE included in this study showed typical
clinical signs (Table 1), as well as MR imaging (Figure 1) and/or
neuropathological features of AHE in the brain (Figure 2). Of
these 11 dogs, 6 were euthanized either immediately after their
clinical evaluation (dogs# 1, 3, 6, 8, 9, 11), or six months (dog#5)
or 27 months later (dog #2) (Table 1). Parents of each of the
affected dogs were clinically normal. Three sets of 2 dogs were
littermates. Dog#9 whelped a litter of clinically normal puppies (6
puppies), 8 months prior to developing clinical signs of AHE.
Dog #2 clinically improved and was neurologically stable
6 months after presentation. He had mild neurological deficits
consisting of proprioceptive placing deficits in all four limbs, and
infrequent generalized seizures. Clinical signs were static for the
next 21 months, followed by a rapid progression. A repeat MRI
showed increased size of the previously defined lesions. The dog
was euthanized 27 months after presentation. Dog #4 is alive 51
months after initial presentation with continuing but static
neurological deficits. An MRI was repeated 12 months after the
initial MRI, and no changes were noted. Dog #5 had static
neurological deficits for 5 months after presentation, but then
developed progressive clinical signs, and was euthanized one
month later. Repeat MRI 4 months after the initial one
demonstrated increased size of the previously noted lesions. Dog
#7 is alive with static neurological deficits 32 months after
diagnosis; Dog #10 is alive 12 months after initial presentation.
However seizures, worsening ataxia and hypermetria developed
4 months after being hit by a car and fracturing the pelvis. The
neurological deficits have been static for the previous 9 months.
Control Alaskan Husky dogs
One normal AH dog with a normal physical, neurological
examination and brain MRI evaluation was admitted into this
study (C#1). Blood samples from 41 apparently healthy normal
AH dogs from three racing kennels were obtained for genotyping.
Control non-Alaskan Husky dogs
Blood samples for genotyping were obtained from 187
randomly chosen canine patients from the VMTH including 51
breeds of both sexes and of varying ages, with a broad spectrum of
clinical diseases. A skin biopsy sample for fibroblast culture was
obtained from one dog with intervertebral disc disease at the time
of laminectomy. Muscle biopsies were collected from one dog with
a fractured femur (from the non-fracture leg) immediately after
euthanasia.
Table 1. Signalment, Presenting Clinical Signs, and Long Term Outcome of Alaskan Huskies with AHE.
Dog # Sex
Age at
presentation
(months) Seizures Tetraparesis
Generalized
Ataxia
Thoracic
Limb Hyper-
metria Dysphagia
Central
Blindness
Longterm
Outcome
1 F 8 Y N Y Y N N Euthanized
2 M 8 Y Y Y Y N N Euthanized
27 months post
diagnosis
3 F 12 N Y Y N Y Y Euthanized
4 F 6 Y Y Y Y N N Alive
5 M 6 Y Y Y Y N N Euthanized
6 months post
diagnosis
6 F 8 N Y Y N Y Y Euthanized
7 F 21 N Y Y N Y N Alive 27 months
post diagnosis
8 M 9 Y Y Y N N N Euthanized
9 F 24 Y N N N N N Euthanized
10 M 8 N N Y Y Y N Alive 7 months
post diagnosis
11 M 6 Y Y Y N N N Euthanized
doi:10.1371/journal.pone.0057195.t001
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Mitochondrial respiratory chain enzyme assays
Respiratory chain enzyme activities were measured in mito-
chondria from liver (Table 2) and skeletal muscle homogenates
(Table 3). There were no major differences between the activities
in the AHE and control dogs either before or after standardization
with citrate synthase and succinate dehydrogenase. Likewise,
pyruvate dehydrogenase complex and 2-14C whole cell oxidation
measurements were normal (data not shown).
Biochemical assays in blood and cerebrospinal fluid (CSF)
No abnormalities were noted on the CBC, CSF and serum
biochemistry analysis in any dog. There was no indication of a
mitochondrial disorder on evaluation of plasma or CSF lactate or
pyruvate levels, or in the lactate to pyruvate ratios.
Neuropathology findings
Seven dogs were euthanized and 5 had a necropsy. In 2 dogs,
only the brain was evaluated pathologically. All dogs had
neuropathological lesions characteristic for AHE with minor
differences in severity among dogs, but not in location. In all
dogs, bilaterally symmetrical areas of cystic encephalomalacia
were grossly visible in the thalamus (Figure 2A).Microscopically,
lesions also included foci of bilaterally symmetrical polioencepha-
lomalacia in the claustrum (Figure 2B(1)), or of necrosis with
Figure 1. (upper panel). MRI images (T2-weighted, transverse) of a normal brain from a clinically normal 1 year old male Alaskan Husky (C#1).
Figure 1 and 2 a are at the level of the head of the caudal nucleus, Figure 1 and 2 b are at the level of the temporomandibular joint, and Figure 1
and 2 c are at the level of the bulla. Lower panel: MR images (T2 weighted, transverse) from the brain of dog #3 with neuropathologically
confirmed AHE. There are multifocal regions of abnormal hyperintensity in the brain, which are bilateral and symmetrical (arrows). a. Hyperintense
lesions are present in the lateral aspect of the caudate nucleus, claustrum and putamen. b. Bilaterally symmetrical lesions in the thalamus and at the
base of the sulci, at the junctional grey and white matter in the cerebral hemispheres. c. Hyperintense lesions in the medulla, vermis of the
cerebellum, and in the cerebrum.
doi:10.1371/journal.pone.0057195.g001
Figure 2. Brain of dog#6. A. Transverse section of brain with bilaterally symmetrical areas of cavitation due to encephalomalacia in the thalamus.
B. Same dog; macrophotograph of a transverse section of brain rostral to Figure 2A illustrating bilaterally symmetrical areas of
polioencephalomalacia [2] or of necrosis with incipient malacia [1,3,4] in cortex deep in the sulci [1], in the claustrum [2], in caudate nucleus [3]
and the globus pallidus [4] (HE-LFB stain).
doi:10.1371/journal.pone.0057195.g002
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incipient malacia (in the deep gray and underlying white matter of
the cerebral cortex confined to the base of the sulci (Figure 2B(1),
in the claustrum (Figure 2B(2), putamen, caudate nucleus
(Figure 2B(3), globus pallidus (Figure 2B(4), pons, and
medulla oblongata. There were similar but milder bilaterally
symmetrical malacic lesions in the deep in the midline of the
ventral lobes of the vermis.
Frozen fresh muscle was histochemically stained and evaluated
by light microscopy in 2 dogs with AHE. In one dog (dog #1) the
muscle was normal. In the other more severely affected dog (dog
#2), deposits of succinic dehydrogenase (Figure 3) and
cytochrome c oxidase positive material were noted, most consistent
with mild mitochondrial proliferation. Ultrastructural lesions in
the skeletal muscle from two affected dogs (dogs #4 and #5) were
compared with one normal AH dog (C#1) (Muscle from dogs #1
and #2 was not evaluated ultrastructurally. Muscle from dogs #4
and #5 was not evaluated by light microscopy). In both dogs #4
and #5, enlarged megamitochondria (2–9 mm diameter, com-
pared to the control dog C#1, where the diameter was 0.5 mm)
were observed with the novel finding of abnormal glycogen
deposits inside the mitochondria. Ultrastructurally, glycogen
accumulation was also found in large aggregates outside the
mitochondria. The mitochondrial cristae were disorganized with
whorls (Figure 4).
Molecular Genetic Studies
Many of the mitochondrial DNA candidates for human Leigh
Syndrome were sequenced in affected dogs (MT-ATP8/6, MT-
tRNALYS, MT-tRNALEU(UUR), MT-tRNASER(AGY), MT-tRNATRY,
MT-tRNATYR, MT-tRNAVAL) with no mutations identified in one
of either blood, liver or fibroblast DNA.
In addition, the following genes were also sequenced: POLG,
Twinkle, DGUOK, RRMB2, MPV17, SUCLA2, SUCLG1, TK2.
Depending on the gene, either gDNA or cDNA from fibroblasts
were sequenced; no mutations were identified in any gene.
Genome Wide Association Study
Whole genome association was performed using 8 AHE affected
dogs (dogs #1–8) and 20 unaffected but related controls. The
genomic inflation factor for this group of samples was 1 indicating
that there was little population stratification. After pruning,
114,613 SNPs were available for analysis. Raw p values showed
a cluster of SNPs located on CFA (Canis familiaris) 25 with values
56 times lower than for the next best associated SNP on CFA 30.
Permutation testing did not give genome wide significance for the
best associated SNPs, however the strong signal from many SNPs
from one discrete location and the absence of any signal from
other chromosomes warranted further investigation. When geno-
types from this area were analyzed, a region of complete
homozygosity was identified in all the affected dogs and never in
the 20 unaffected dogs. The region of homozygosity extended 3.5
Mb between 41074763 and 44542154 (Figure 5).
SLC19A3 Expression
Evaluation of this region for candidate genes uncovered
SLC19A3 as a likely candidate, based on the phenotypic
similarities between people affected with biotin-responsive basal
ganglia disease (BBGD) and dogs with AHE. In the canine genome
there has been a duplication of SLC19A3 and there are two
paralogs, SLC19A3.1 (43,411,960–43,419,612 Mb) and SLC19A3.2
(43,363,905–43,386,983 Mb). SLC19A3.1 shares 84.7% identity
and SLC19A3.2 shares 79.9% identity at the amino acid level with
the human gene. In order to determine which gene was the more
likely candidate, the tissue specific expression levels of each gene
were evaluated (Figure 6). SLC19A3.1 was expressed in the
cerebrum, cerebellum and spinal cord while SLC19A3.2 was not.
Table 2. Respiratory chain enzyme rates in liver of dogs with AHE.
Dog # CI+III* (nmol/mg/min) CI+III/CS CII+III (nmol/mg/min) CII+III/CS CIV (nmol/mg/min) CS (nmol/mg/min) CIV/CS
C#1 1.53 0.30 4.64 0.90 10.81 5.15 2.10
1 2.27 0.51 3.24 0.74 14.20 4.41 3.22
3 2.02 0.47 1.00 0.23 4.55 4.27 1.07
4 1.34 0.36 1.58 0.42 7.68 3.73 2.06
5 1.54 0.29 1.98 0.37 12.60 5.35 2.36
*CI+III (complex I+III), NADH: cytochrome c reductase; CII+III (complex II+III), succinate:cytochrome c reductase; CIV (complex IV), cytochrome oxidase; CS (citrate
synthase).
doi:10.1371/journal.pone.0057195.t002
Table 3. Respiratory chain enzyme rates in skeletal muscle of
dogs with AHE.
Complex Dog #1 Dog #2
Dog #2
(repeat)
Control non AH
Dog
I+III 1.05 1.01 3.45 0.72
I 31.74 30.66 35.91 28.52
II+III 0.74 0.73 0.91 0.32
IV 2.66 2.65 3.23 2.30
SDH 1.41 1.15 1.77 0.64
CS 40.43 31.29 34.96 33.70
Values/CS
I+III 0.026 0.032 0.098 0.021
I 0.79 0.98 1.03 0.85
II+III 0.018 0.023 0.026 0.0094
IV 0.066 0.085 0.092 0.068
SDH 0.035 0.037 0.051 0.019
Values/SDH
I+III 0.74 0.88 1.95 1.12
I 22.51 26.7 20.20 52.66
II+III 0.52 0.63 0.51 0.50
IV 1.89 2.30 1.82 3.59
CS 28.67 27.2 19.75 52.7
*SDH = succinate:dehydrogenase; CS = citrate synthase.
doi:10.1371/journal.pone.0057195.t003
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In addition, SLC19A3.1 had higher nucleotide homology to the
human locus, therefore it was pursued as the best regional
candidate gene.
SLC19A3 Sequencing
The coding region of SLC19A3.1 was sequenced as well as some
intronic sequences. Four changes were identified in dogs with
AHE relative to both the canfam2 Boxer sequence and an
unaffected AH control (Table 4). A 4 bp insertion (c.624
insTTGC) and SNP (c.625 C.A) in exon 2 were the most
compelling changes since they were predicted to result in a frame
shift and premature peptide termination which would truncate
279 amino acids of the 498 amino acid full length protein
(Figure 7). In order to test additional animals, a genotyping assay
based on PCR product size was developed for this insertion. All 11
dogs with AHE were homozygous for the mutation, 26/41
unaffected AH dogs were homozygous wild type and 15/41
unaffected AH dogs were determined to be heterozygous carriers.
In order to determine if the deletion was just a polymorphism, 187
dogs from 51 breeds were genotyped and the mutant allele was not
identified. Expression levels of SLC19A3.1 were compared in
cerebral cortex tissue from a dog affected with AHE and an
unaffected beagle sample and SLC19A3.1 expression was dramat-
ically decreased in the affected dog (Figure 8).
Discussion
We have demonstrated in this study that a homozygous
mutation in the SLC19A3.1 gene encoding a thiamine transport
protein is strongly associated with AHE. Each of the 11 dogs with
AHE had a homozygous mutation of SLC19A3.1, and 15/41
clinically normal AH dogs had a heterozygous mutation while the
other 26 had wild type homozygosity. No such mutation was
found in any of the 187 non-AH dog breeds. Although AHE has
been claimed to be a primary mitochondrial encephalopathy
based on clinical and pathological similarities to LS, no mutations
were found in any of the candidate canine nuclear or mitochon-
drial genes linked to human LS. In dogs with AHE, biochemical
analysis failed to demonstrate defects in the mitochondrial
respiratory chain enzyme activities in liver, skeletal muscle or
cultured fibroblasts, considered characteristic of LS. Together,
these findings strongly suggest that the pathogenesis of AHE
involves a primary defect in a thiamine transporter protein in the
CNS and is not due to a primary mitochondrial encephalopathy.
However, the AHE phenotype is consistent with a secondary
mitochondrial disease.
Solute carrier family 19 (SLC19) is a group of genes that
transport water-soluble vitamins into cells. [10] There are 3
members in the family, SLC19A1, SLC19A2 and SLC19A3. The
SLC19A1 gene encodes folate transporter 1 protein, regulating
intracellular levels of folate, as well as mediating methotrexate
transport. The SLC19A2 gene encodes the human thiamine
transporter 1 (hTHTR1) protein whereas human thiamine
transporter 2 (hTHTR2) protein is encoded by the SLC19A3
gene. SLC19A2 and SLC19A3 are structurally and functionally
similar and thiamin (vitamin B1) is transported across the cell
membrane by both thiamine transporters. All SLC19 family genes
are expressed ubiquitously, although at variable levels in different
tissues [10]. The dog is unusual in that it has two SLC19A3
paralogs, compared with only one each in mice and people [11].
In the dog, expression of SLC19A3 is also ubiquitously distributed,
but the relative tissue expression varies depending on the specific
paralog. In this study, we demonstrated that the CNS has high
tissue expression of the SLC19A3.1 compared with SLC19A3.2 with
SLC19A3.2 expressed at low levels in the CNS. This finding
suggests that SLC19A3.2 in the CNS cannot compensate for a
functional loss of thiamine transport caused by the defective
SLC19A3.1. In people, SLC19A3 is expressed at high levels in
kidney, liver and placenta, with low levels in other tissues,
including the brain [12]. The highest level of SLC19A3 RNA
expression in the human brain is in the thalamus [6]. If the same
holds true in the dog, the need for relatively high SLC19A3 RNA
expression in the thalamus could explain the location of the most
severe lesions in dogs with AHE [2].
Thiamine is an essential nutrient and thiamine deficiency (TD)
may cause bilaterally symmetrical brain lesions in domestic
Figure 3. Frozen muscle section from dog #2, histochemically
stained with succinic dehydrogenase (SDH). There are areas of
excessive SDH positive staining (arrow) in two myofibers, most
consistent with mild mitochondrial proliferation.
doi:10.1371/journal.pone.0057195.g003
Figure 4. Fixed muscle (dog #4). Transmission electron microsco-
py. Glycogen deposits (arrowhead) are present in the abnormal
megamitochondria (arrow).
doi:10.1371/journal.pone.0057195.g004
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Figure 5. Genome wide association analysis of Alaskan Husky encephalopathy. A. Manhattan plot of –log 10 of raw p values (y axis) by
chromosome (x axis). The best associated SNP (p = 6.5961026) was located at 43980115 Mb on Cfa 25 B. –log 10 of the permuted (100,000)p values (y
axis) are plotted by chromosome (x axis). The lowest p value (0.051) was obtained for the same SNP located at 43980115 Mb. C. The Chi square value
shown in grey and the allele frequency shown in black on the y axis are plotted against the Mb (x axis) on CFA 25. The location of the two paralogs of
SLC19A3 are shown within the region of homozygosity identified in the affected individuals at the top of the figure.
doi:10.1371/journal.pone.0057195.g005
Figure 6. The relative tissue specific expression levels of the two paralogs of SLC19A3 and GAPDH. RT PCR products obtained from equal
amounts of cDNA are shown from the following tissues: 1 spleen, 2 skin, 3 cerebellum, 4 thymus, 5 testis, 6 spinal cord, 7 heart, 8 muscle, 9 cerebral
cortex, 10 kidney, and 11 liver.
doi:10.1371/journal.pone.0057195.g006
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animals and people [7,13,14]. Thiamine, a B-complex, water-
soluble essential vitamin, has a fundamental role in carbohydrate
metabolism in all cells and a critical role in mitochondrial
metabolism [15,16]. Because of the critical dependence of the
CNS on mitochondria for energy metabolism, TD can lead
rapidly to severe neurological deficits. In dogs, the classical
histological lesion of TD (both experimental and spontaneous) is
bilaterally symmetrical polioencephalomalacia, confined to the
brain stem nuclei, periventricular grey matter, claustrum, lateral
geniculate nuclei, caudal colliculi, occipital and parietal cortex,
and cerebellar nodulus. Lesions in the caudal colliculus are the
hallmark of dietary thiamine deficiency encephalopathy in dogs.
Dogs with experimental TD also have cardiac lesions [7]. The
distribution of these lesions in the dog differs from those in people,
in whom the mammillary bodies are mainly affected, and
involvement of the cerebral cortex is more pronounced.
While dogs with TD and AHE have the same histological
lesions of bilaterally symmetrical encephalomalacia, anatomic
patterns of lesion distribution are distinctively different. Dogs with
AHE do not have lesions in the caudal colliculus or lateral
geniculate nucleus, and dogs with TD do not have thalamic lesions
[2,7]. In people with spontaneous TD (Wernicke’s encephalopa-
thy) who are still responsive to thiamine administration, the lesions
are mainly confined to the mammillary bodies. While it is unlikely
that the pathogenesis of AHE is due to an absolute global TD,
these findings may be consistent with a localized TD, resulting
from the functional mutations apparently restricted to the tissue
distribution of the SLC19A3.1 gene.
There is a phenotypic spectrum of diseases in people associated
with abnormalities in different regions of the SLC19A3 gene,
including biotin-responsive basal ganglia disease (BBGD) [17],
Wernicke’s-like encephalopathy (WLE)[6], and an encephalopathy
described in 4 related Japanese boys [9]. People with BBGD have
vague clinical signs including confusion and vomiting, progressive
loss of motor function, dysarthria, dysphagia, cogwheel rigidity,
and seizures, which are ultimately fatal if untreated. The major
features on brain MRI are areas of bilaterally symmetrical
polioencephalomalacia of the caudate and putamen nuclei [17].
Two homozygous missense mutations (c.68G.T; p.G23V; and
c.1264A.G, p.T422A) in SLC19A3 have been identified. In
patients with either mutation, no clinical response is noted
following thiamine administration. However, if treated with biotin
early in the course of disease, the clinical signs may be reversed
[17]. In two adult siblings with BBGD, two heterozygous
mutations in SLC19A3 (c.74dupT/p.Ser26LeufsX19 and c.980-
14 A.G) led to a premature termination codon (PTC), and a loss
Figure 7. DNA sequence of the mutation identified in AHE. A.
wildtype sequence, B. Heterozygous carrier, C. Mutant sequence.
doi:10.1371/journal.pone.0057195.g007
Figure 8. The relative expression levels of SLC19A3.1 in canine
cerebral cortex. RT PCR from equal amounts of RNA isolated from a
normal beagle and an Alaskan husky sled dog affected with AHE.
doi:10.1371/journal.pone.0057195.g008
Table 4. Sequencing results of SLC19A3 in dogs with AHE.
Mutation Location Change in DNA (59 to 39) Change in Protein
12 bp insertion intron 1 chr25:43,417,532 [191 bp downstream from
ex2 (chr25:43,417,341)]
CTTTCTTTCTTT none
SNP 1 exon 2 chr25:43,417,105 C.T none
SNP 2 exon 2 + 4 bp insertion chr25:43,416,868 G.T + TTGC Amino Acid 208: Gln.His, out of frame
for 10 AA, protein termination at AA 219
8 bp deletion intron 2 chr25:43,414,774-43,414,781 [79 bp downstream
ex 3 (chr25:43,414,702)]
AAATAAAT none
SNP exon 5 chr25:43,411,974 A.G Amino Acid 490: Thr.Ala
doi:10.1371/journal.pone.0057195.t004
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of function mutation of SLC19A3. One patient responded to
biotin, but the other did not improve with biotin administration
until thiamine was concurrently supplemented.[18] However,
since hTHTR2 does not transport biotin, both the pathophysiol-
ogy of BBGD, and the response to therapy with biotin imply that a
more complex mechanism than simple thiamine deficiency causes
these lesions [19]. For example, perhaps the truncated form of the
transporter is still able to transport biotin albeit not to the same
level as the wild type form, or perhaps since biotin is an important
cofactor of many carboxylases in mitochondria, biotin supple-
mentation may exert a compensatory effect.
WLE was reported in 2 Japanese brothers in their second
decade of life. Clinical signs included diplopia, external ophthal-
moplegia, ptosis, seizures, nystagmus and ataxia. On brain MRI
there were hyperintensities on the FLAIR (fluid attenuated
inversion recovery) sequences bilaterally in the thalamus and
periaqueductal region, which are entirely consistent with actual
Wernicke’s encephalopathy (thiamine deficiency encephalopathy).
A compound heterozygous mutation of p.K44E and p.E320Q was
found in SLC19A3, resulting in approximately 60% thiamine
intracellular uptake in Chinese hamster cells transfected with
constructs containing either p.K44E or p.E320Q cDNA compared
to the wild-type. Neither patient had serum thiamine deficiency,
but both patients responded clinically to thiamine [6].
In four related Japanese boys with infantile seizures, psycho-
motor retardation, and characteristic lesions on brain MRI (focal
T2W hyperintensity in bilateral symmetrical thalamic and basal
nuclei, with cerebellar and cerebral cortical atrophy), a homozy-
gous mutation was found (c.958G.C, p.E320Q) in SLC19A3.
There was no change in either neurological symptoms or brain
MRI lesions in response to biotin administration in the one boy
who was treated [9].
In BBGD, WLE, and in the Japanese boy encephalopathy,
there is a distinct genotype-phenotype correlation. Patients
affected by each disease have a remarkably similar phenotype.
While the BBGD phenotype is thought to be secondary to a loss-
of-function mutation, the Japanese boy encephalopathy may be
due to a toxic gain-of-function secondary to the SLC19A3mutation
[9]. Further investigations are needed to characterize the function
effects of these SLC19A3 mutations and the associated genotypic-
phenotypic correlation.
Dogs with AHE did not have any biochemical evidence of
primary mitochondrial disease in liver, skeletal muscle or
fibroblasts, but did have subtle evidence of mitochondrial
pathology. By light microscopy, there was prominent mitochon-
drial hyperplasia in muscle and liver and ultrastructural exami-
nation of muscle revealed ‘‘megamitochondria’’ and abnormal
glycogen deposits. However such abnormal mitochondrial mor-
phology is not necessarily evidence of a primary mitochondrial
disease. The observed mitochondrial changes could be epiphe-
nomenal, reflective of a response to a defect in energy metabolic
pathways as expected with a defective SLC19A3 gene, especially in
an active racing breed.
In conclusion, we have demonstrated that a homozygous
mutation in SLC19A3.1, a gene encoding a thiamine transport
protein in the brain, is strongly associated with AHE. The
mutation is homozygous in dogs with AHE while unaffected AH
are either homozygous wild type or heterozygous for the mutation.
While our findings are consistent with the mutation identified
being widespread in AH from North America, we do not know to
what extent this or similar mutations might be causal to AHE
worldwide. We are hopeful that the findings from this study will
help in future studies to test for this mutation in AH from Europe
and other regions of the world. While the pathologic findings in
AHE are not consistent with classical experimental or spontaneous
global TD, they may be consistent with localized TD or may
suggest more complex pathways involved with thiamine metab-
olism in the CNS. This large animal model may allow for
prospective investigations into the mechanisms of SLC19A3 related
syndromes and the potential role of thiamine and/or biotin as a
therapeutic strategy.
Materials and Methods
Criteria for inclusion into the study
a. Alaskan Husky dogs with AHE. Alaskan Husky dogs
with clinical signs suggestive of AHE, including generalized
seizures, gait abnormalities, dysphagia and ataxia [1] (see
Table 1), were examined at the VMTH. Dogs had physical
and neurological examinations completed by one author, a board
certified veterinary neurologist (KV). Dogs that were subsequently
euthanized had an immediate necropsy evaluation. For dogs not
clinically evaluated at the VMTH, brain MR images were
reviewed by four authors (KV, PD, BS and RJH), and/or the
formalin fixed brain examined neuropathologically by a board
certified veterinary pathologist (RH) and a human neuropatholo-
gist(AWB). Neuroimaging and neuropathological lesions that were
inclusion criteria for dogs with AHE included bilaterally symmet-
rical, cavitatory malacic lesions in the thalamus, and smaller
malacic lesions in the putamen, claustrum, junctional grey and
white matter in the cerebral cortex, in the brainstem and midline
cerebellar vermis (Figure 1, 2A and 2B). [2] All lesions were
hyperintense on T2W MR images.
b. Control Alaskan Husky dogs. Inclusion criteria for the
one healthy, negative control AH was an age greater than one year
of age, normal physical and neurological examination, and normal
MRI of the brain with no detectable lesions in T1-weighted (T1W)
pre- and post contrast, T2-weighted (T2W), proton density
weighted, and FLAIR images in both the transverse and sagittal
planes. Inclusion criteria for the other dogs were that they were
reportedly healthy, older than one year of age, actively racing AHs
of both sexes.
c. Control non-Alaskan Husky dogs. Non-Alaskan Husky
control dogs were randomly selected from canine patients of both
sexes and of varying ages admitted to the VMTH during the study
period. These control dogs had a wide range of clinical diseases
such as kidney disease and intervertebral disc disease, but none
had similar clinical signs to AHE. All studies were done with their
owner’s consent, and in strict accordance with good animal
practice, with study protocols approved by the Institutional
Animal Care and Use Committee (IACUC) at UC Davis.
Tissue Culture
Skin biopsies were obtained and fibroblasts were grown and
maintained in Eagle’s minimal essential medium culture medium,
containing 2 mM glutamine (Invitrogen, Burlington, ON,
Canada), 1% penicillin/streptomycin and 20% fetal calf serum
(Wisent, St-Bruno, Quebec, Canada).
Mitochondrial Respiratory Chain Enzyme Assays in
Skeletal Muscle, Liver and Cultured Fibroblasts
Skeletal muscle and liver specimens were collected under
general anesthesia or at necropsy and immediately frozen. Enzyme
activities in both skeletal muscle and liver samples were assayed for
NADH:cytochrome c reductase (Complex I+III), citrate synthase
activity, succinate cytochrome c reductase (complex II+III) [20],
cytochrome oxidase (complex IV) [21] and standardized with
respect to citrate synthase and succinate dehydrogenase. 2-14C
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pyruvate whole cell oxidation was measured from cultured
fibroblasts as previously described [22] and total pyruvate
dehydrogenase complex activity was measured in both the native
and the dichloroacetate activated state [23].
Biochemical Assays in Blood and Cerebrospinal fluid
(CSF)
Complete blood cell counts, serum biochemistry profiles,
urinalysis and CSF analysis were done at the VMTH. Pyruvate
and lactate concentrations were measured in both CSF and
plasma. Plasma samples were obtained at rest and following 10
minutes of strenuous exercise were collected and evaluated at the
Comparative Neuromuscular Laboratory, School of Medicine,
UC San Diego, as previously described [24].
Pathology
Fresh tissue samples (skin, skeletal muscle and liver) were
obtained either by surgical biopsy under general anesthesia or
immediately after euthanasia. Muscle biopsy specimens were
collected from the vastus lateralis and triceps brachii muscles and
frozen immediately using isopentane precooled in liquid nitrogen.
A standard panel of histochemical stains and reactions was
performed on cryostat sections (10 mm thick) including HE,
myofibrillar adenosine triphosphatase at pH 9.8, 4.5 and 4.3,
modified Gomori trichrome, periodic acid-Schiff hematoxylin,
esterase, staphylococcal protein A-horseradish peroxidase, oil red
O, nicotinamide adenine dinucleotide tetrazolium reductase,and
acid phosphatase as previously described [25].
Table 5. PCR primers for amplification of mtDNA and nuclear genes.
Forward primer Reverse primer
mtDNA (gDNA)
MT-tRNALYS, MT-ATP8, MT-ATP6 DogATP8F 59-CTGATCTGCCTTAATAGTATAACCT-39 DogATP6R 59-GGTCATGGGCTTGGGTTG-39
MT-tRNAVAL Dog tRNAVal-F 59-AAAACACAAGAGGAGACAAGTCG -39 Dog tRNAVal-R 59-
CGGTACTATCTCTATCGCTCCAA-39
MT-tRNALEU(UUR) DogtRNA-LeuF 59-AACCTCCCCCAGTACGAAAG-39 DogtRNA-LeuR 59-AGGCTACGGCAAGAAGGATT-39
MT-tRNASER(AGY) DogtRNA-Ser2F 59-TGCCCCTACTCCTCCTATCC -39 DogtRNA-Ser2R 59-TCTGGAGTTGCACCAATTTTT-39
MT-tRNATRY, MT-tRNATYR DogtRNA-TrpF 59-AAAAAGGCAACCCTATTACCC-39 DogtRNA-TyrR 59-GATGAGGAGGCTCAAAGCAG-39
Nuclear genes (cDNA unless noted)
POLG (4 parts) DogPOLG-F 59-CTTTCGGCCAGTAAAAGCAG-39 POLG-R5 59-AGTTCCCTCTGCCAAGCA-39
DogPOLG-F1 59-GCGGCCAACTCGTTATTG-39 DogPOLG-R1 59-CCCCCATCTCCAACATGC-39
DogPOLG-F2 59-GGACGTGTGGGCTACCTATG-39 DogPOLG-R2 59-ATGCCGCTCCGAGTAGTG-39
DogPOLG-F3 59-CGGGTCACTCCAAAACTCAT-39 DogPOLG-R3 59-CCATACCACCATCTGGGAAC-39
Twinkle Dog-twinkle-F 59-TAGTAAAGGCACCCGAACCA-39 Dog-twinkle-R 59-GCCTTAGCAGAGGGCTAAGAA-
39
TK2 (in two parts) (gDNA) Dog-TK2-F 59-GCCTTTAGGTGGATTGGACTG-39 Dog-TK2-int1R 59-CTGGGCCTTCTTTGACCTTA-39
(cDNA) DogTK2-ex3F 59-ATCTGTGTTGAGGGCAATAT-39 DogTK2-R2 59-CTATGAACCATGTTTCTGATTCTCTG-
39
DGUOK DogDGUOK-F 59- AAATGTTCTCGGCGGAAGT-39 DogDGUOK-R 59-
TGCAAAGTCGAAGACTAATACCA-39
SUCLG1 (2 parts) DogSUCLG1-F 59-AATTCATTCAGGCGACTGCT-39 DogSUCLG1-R1 59-TTGATGATTCCAGGGCAGTT-39
DogSUCLG1-F1 59-AGGACATGGTACGGGTCAAG-39 DogSUCLG1-R 59-CTTGCTGTACCGACAGACCA-39
SUCLA2 (in two parts) (gDNA) Dog-SUCLA2-F 59-CATTTGATATTTGGCTGGAGGT-39 Dog-SUCLA2-ex2R 59-ATTCCTTTGTTGCTGCTGCT-
39
(cDNA) Dog-SUCLA2-F3 59-TTCTGGGAAGTTCTGGATTTTT-39 Dog-SUCLA2-R1 59-ATGCACAGCACAGTTCCATC-39
MPV17 (3 parts) (gDNA) DogMPV17-F4 59-AGCCAAGCGCTCTTTAATTG-39 DogMPV17int1R 59-TGTGGTGAGGTGAGCTTCTG-
39
DogMPV17int1F 59-GGGACTTATTCCCTACCTGGA-39 DogMPV17int4R 59-ACCAAACCTGCCTTGTTCC-39
DogMPV17int4F 59-GGTCTTTGAACTGGTCTGTGC-39 DogMPV17int6R 59-GCTGTGTCCAGCTGTTGTGA-39
RRMB2 Dog-RRM2B-F 59-CTCTGCCGGAGTTGGAGGT-39 Dog-RRM2B-R 59-TTCCCTAAGGAGGTGCTTTACA-
39
SLC19A3.1 (gDNA) Exon 1 59-CACCAGCCAGGGTTGTACTT-39 59-GGTTTAGCGCCTGCCTTT-39
Exon 2 59-AGAAGGGGGAGGACCTCTTT-39 59-TTTCTTCCAGTGCCTTCCAT-39
Exon 3 59-GCAAGTGACAGGGTTTATGGA-39 59-AAAAATCACAACCCGACAGTG-39
Exon 4 59-TGGTGTTTTAATTCAGCCTTCA-3 59-TATGGCAGGAGGAAAAGCAG-39
Exon 5 59-TGGACCAGACCTGGAGATTC-39 59-CTGCTTTTCCTCCTGCCATA-39
SLC19A3.2 59-TTCTTGGGTTTTTCCCACAG-39 59-CTCTCCCAGGAGATCCCAGT-39
SLC19A3 59-AGCCCAGAGCACTACCAGAA-39 59-GGGCTCATCTGGATTCTGAC-39
GAPDH 59-AAGATTGTCAGCAATGCCTCC-39 59-CCAGGAAATGAGCTTGACAAA-39
doi:10.1371/journal.pone.0057195.t005
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Dogs with AHE euthanized at the VMTH had an immediate
necropsy evaluation. The CNS and other issues were immersion-
fixed in 10% formalin, and selected tissues were then routinely
embedded in paraffin, sectioned at 5 mm and evaluated after HE
staining. Selected brain sections were also histochemically stained
with HE-Luxol fast blue. For transmission electron microscopy,
skeletal muscle specimens were immersion fixed in 3% glutaral-
dehyde in buffer, routinely processed and embedded in plastic
resin. Thick sections were stained with toluidine blue and
appropriate thin sections selected for transmission electron
microscopic evaluation as previously described [26].
Molecular genetics techniques for candidate genes
Genomic DNA was isolated from cultured fibroblasts, blood or
tissue using a Puregene genomic DNA isolation kit (Inter Medico,
Markham, ON, Canada). RNA was isolated using Trizol (Life
Technologies, Burlington, ON, Canada). Full length cDNA
sequences were generated using RT-PCR and Superscript II
reverse transcriptase and amplified using Platinum Hi-Fi Taq
polymerase (Life Technologies, Burlington, ON, Canada). Oligo-
nucleotide primers used for routine PCR (IDT, Iowa, USA) are
listed in Table 5. All products were sequenced by fluorescent
sequencing methods as recommended (ACGT Corp., Toronto,
ON, Canada).
Genome Wide Association
DNA extracted from blood samples from AHE and control dogs
was genotyped using the Illumina HD canine array (Illumina Inc,
San Diego, California). Association analysis was performed using
PLINK software [27] (Shaun Purcell, URL: http://pngu.mgh.
harvard.edu/purcell/plink/). Population stratification was evalu-
ated by determining that the genomic inflation value was 1.0.
SNPs with a minor allele frequency above 0.01 were used for the
association analysis. Individuals with more than 15% missing calls
were excluded from the analysis. SNPs with more than 10%
missing genotypes were also excluded. 100,000 permutations were
used to determine significance of associations. Genotypes were
evaluated for homozygosity in affected individuals by visual
inspection.
Verification of SLC19A3.1 Structure
To verify the structure of exon 2 in paralog SLC19A3.1, cDNA
from a control sample was sequenced for this region and then
compared to genomic sequence of canine genome assembly
canfam 2.
PCR and Sequencing of positional candidate gene
SLC19A3
Each of the 5 exons of SLC19A3.1 were amplified and
sequenced in at least one dog with AHE and one control dog of
a different breed. For areas of further interest, additional samples
were sequenced from a dog with AHE, an unaffected AH, and an
unaffected non-Alaskan Husky dog.
PCR was performed using primers that allowed amplification of
all exons and intron/exon boundaries. Reactions were performed
on an Applied Biosystems Gene Amp PCR System 9700. Each
reaction consisted of 13.9 ml water, 2 ml 10X buffer with MgCl2,
1 ml dNTP, 1 ml of each primer, 0.1 ml of DNA Taq Polymerase,
and 1 ml of DNA. Cycling programs were based on the primers’
Tm and the expected product size. Amplified samples were then
sequenced on an Applied Biosystems 3100 Genetic Analyzer using
the Big Dye Terminator Sequencing Kit. Sequences were aligned
using VectorNTI software (Life Technologies, Burlington, ON,
Canada).
Genotyping
In order to screen a large number of normal control dogs,
comprising both AH and other breed dogs, for the 4 bp insertion
and SNP identified in exon 2, a PCR genotyping assay was
developed using the following primers: 59 6FAM-
ATCCTTGGCCTCTGTCTGTG, 39-TAGGCATTGGGC-
TATTCACC. Genotyping was performed by fragment size on
an Applied Biosystems 3100 Genetic Analyzer. Genotypes were
analyzed using STRand software [28].
RT-PCR
Semiquantitive RT-PCR was performed to compare the tissue
expression of SLC19A3.1 to that of SLC19A3.2, using cDNA made
from 11 different tissues (spleen, skin, cerebellum, thymus, testis,
spinal cord, heart, muscle, cerebral cortex, kidney, and liver) from
one control dog (non-husky) sample. A reaction for the house-
keeping gene GAPDH was also done to serve as a baseline to
ensure equal concentrations and quality of the samples for
expression comparison. RT-PCR was then performed using
RNA extracted from both the cerebral cortex of an affected and
an unaffected non-AH dog to directly compare expression of
SLC19A3.1 in the brain.
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